Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019
August 27 2019 - 6:36PM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular
medicines for inflammatory diseases, will host a webcast to discuss
the financial results for the period ending June 30, 2019.
The webcast will begin at 6.00pm EDT Thursday,
August 29, 2019; 8.00am; AEST Friday, August 30, 2019. It can be
accessed via
https://s1.c-conf.com/diamondpass/mesoblast-10001891-invite.html
To access the call only, dial 1 855 881 1339
(U.S.), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187
(outside of the U.S. and Australia). The conference identification
code is 10001891.
The archived webcast will be available on the Investor page of
the Company’s website: www.mesoblast.com
About Mesoblast Mesoblast Limited (Nasdaq:
MESO; ASX:MSB) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary technology platform to establish a broad portfolio of
late-stage product candidates with three product candidates in
Phase 3 trials – acute graft versus host disease, chronic heart
failure and chronic low back pain due to degenerative disc disease.
Through a proprietary process, Mesoblast selects rare mesenchymal
lineage precursor and stem cells from the bone marrow of healthy
adults and creates master cell banks, which can be industrially
expanded to produce thousands of doses from each donor without the
need for tissue matching. Mesoblast has facilities in Melbourne,
New York, Singapore and Texas and is listed on the Australian
Securities Exchange (MSB) and on the Nasdaq (MESO).
www.mesoblast.com
For further information, please contact:
Julie Meldrum
Corporate Communications
T: +61 3 9639
6036
E:
julie.meldrum@mesoblast.com
Schond Greenway Investor Relations T: +1 212 880 2060E:
schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024